While Sensex gains over 2%, these pharma stocks are in focus
These are the 5 stocks from the pharma sector that are in focus today.
Sun Pharmaceutical Industries Ltd: "Taro Pharmaceuticals USA, one of the wholly-owned subsidiaries of our Taro Pharmaceutical Industries, has agreed to acquire all of the outstanding capital stock of Galderma Holdings Inc (incorporated in Delaware); Proactiv YK (incorporated in Japan); The Proactiv Company Corporation (incorporated in Canada); and other assets of The Proactiv Company Sari, used in the business of developing, manufacturing, marketing, selling and distributing products sold under the Proactiv, Restorative Elements and In Defense of Skin brands," Sun Pharmaceutical said in an exchange filing.
At 10 AM, Sun Pharma was trading up by 0.45%.
Zydus Lifesciences Ltd: Sentynl Therapeutics Inc, a US subsidiary of Zydus Lifesciences, announced the execution of an asset purchase agreement for the sale of BridgeBio's Nulibry (Fosdenopterin) for injection. Nulibry is approved by the US Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type-A, an ultra-rare, life-threatening pediatric genetic disorder.
At 10 AM, Zydus Lifesciences Ltd was trading up by 0.68%.
Alembic Pharmaceuticals Ltd: Alembic Pharmaceuticals Ltd has announced that its joint venture, Aleor Dermaceuticals Ltd (Aleor), has received final approval from the US health regulator for its generic version of Nystatin and Triamcinolone Acetonide ointment used for the treatment of cutaneous candidiasis.
At 10 AM, Alembic Pharmaceuticals Ltd was trading up by 1.16%.
Natco Pharma Ltd: Natco Pharma Ltd along with its marketing partner Arrow International launched its first generic version of Revlimid (Lenalidomide capsules), in the US market. The capsules are used in the treatment of multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes and mantle cell lymphoma.
At 10 AM, Natco Pharma Ltd was trading up by 1.68%.
Venus Remedies Ltd: Venus Remedies Ltd, one of India's leading research-driven pharmaceutical companies has received the coveted WHO Good Distribution Practices (GDP) certification from Societe Generale de Surveillance (sGS), the world's leading testing, inspection and certification company in a resounding endorsement of its quality services throughout the entire supply chain cycle.
At 10 AM, Venus Remedies Ltd was trading up by 3%.
About the Author
Start Investing Now!
Open Free Demat Account in 5 mins